105 related articles for article (PubMed ID: 28635153)
21. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis.
Montes AF; Villarroel PG; Ayerbes MV; Gómez JC; Aldana GQ; Tuñas LV; Fernández MS; Fernández MJ
J Cancer Res Ther; 2017; 13(2):240-245. PubMed ID: 28643741
[TBL] [Abstract][Full Text] [Related]
23. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
[TBL] [Abstract][Full Text] [Related]
25. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
[TBL] [Abstract][Full Text] [Related]
26. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
Park SR; Kim MJ; Nam BH; Kim CG; Lee JY; Cho SJ; Kong SY; Park YI
Eur J Cancer; 2017 Sep; 83():32-42. PubMed ID: 28711577
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
Shiroyama T; Tamiya M; Minami S; Takata S; Masuhiro K; Futami-Nishijima Y; Uenami T; Mori M; Koba T; Matsuki T; Takimoto T; Suzuki H; Okamoto N; Komuta K; Hirashima T; Kumanogoh A; Kijima T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):461-467. PubMed ID: 28688052
[TBL] [Abstract][Full Text] [Related]
28. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.
Bianconi D; Heller G; Spies D; Herac M; Gleiss A; Liebmann-Reindl S; Unseld M; Kieler M; Scheithauer W; Streubel B; Zielinski CC; Prager GW
Sci Rep; 2017 Jul; 7(1):4851. PubMed ID: 28687745
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy.
Jensen BES; Hansen JM; Larsen KS; Junker AB; Lassen JF; Jensen SE; Schaffalitzky de Muckadell OB
Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1118-1125. PubMed ID: 28678044
[TBL] [Abstract][Full Text] [Related]
30. Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Pellini Ferreira B; Vasquez J; Carilli A
Am J Med Sci; 2017 Jun; 353(6):610-612. PubMed ID: 28641727
[No Abstract] [Full Text] [Related]
31. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Okuno T; Wakabayashi M; Kato K; Shinoda M; Katayama H; Igaki H; Tsubosa Y; Kojima T; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Kato H; Nakamura K; Fukuda H; Ishikura S; Ando N; Kitagawa Y;
Int J Clin Oncol; 2017 Dec; 22(6):1042-1049. PubMed ID: 28717855
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.
de Azevedo CRAS; Thuler LCS; de Mello MJG; de Oliveira Lima JT; da Fonte ALF; Fontão DFS; Carneiro VCG; Chang TMC; Ferreira CG
Gynecol Oncol; 2017 Sep; 146(3):560-565. PubMed ID: 28709705
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent.
Fountzilas C; Chhatrala R; Khushalani N; Tan W; LeVea C; Hutson A; Tucker C; Ma WW; Warren G; Boland P; Iyer R
Cancer Chemother Pharmacol; 2017 Sep; 80(3):497-505. PubMed ID: 28702772
[TBL] [Abstract][Full Text] [Related]
34. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
35. Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report.
Shirakawa T; Hirata T; Maemura K; Goto T; Shimao Y; Marutsuka K; Ueda Y; Kikuchi I
Mol Clin Oncol; 2017 Jul; 7(1):93-97. PubMed ID: 28685083
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
[TBL] [Abstract][Full Text] [Related]
37. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Yu A; Faiq N; Green S; Lai A; Green R; Hu J; Cloughesy TF; Mellinghoff I; Nghiemphu PL
J Neurooncol; 2017 Sep; 134(2):357-362. PubMed ID: 28669012
[TBL] [Abstract][Full Text] [Related]
38. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).
Ohnishi S; Watari H; Kanno M; Ohba Y; Takeuchi S; Miyaji T; Oyamada S; Nomura E; Kato H; Sugiyama T; Asaka M; Sakuragi N; Yamaguchi T; Uezono Y; Iwase S
J Gynecol Oncol; 2017 Sep; 28(5):e44. PubMed ID: 28657216
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
